KA · Kineta, Inc./De - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | $0 | $0 | - | $200.0K | $5.16M | $281.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $617.0K | - | $898.0K | $1.00M | $2.73M | - | $1.91M | $2.71M | $2.84M | - |
| SG&A | $1.40M | - | $1.16M | $1.59M | $3.68M | - | $2.08M | $3.43M | $3.92M | - |
| Total Operating Expenses | $2.02M | - | $2.06M | $2.59M | $6.41M | - | $3.99M | $6.14M | $6.77M | - |
| D&A | $0 | - | $0 | $0 | $0 | - | $15.0K | $18.0K | $2.0K | - |
| Operating Income | ($2.02M) | - | ($2.06M) | ($2.59M) | ($6.41M) | - | ($3.99M) | ($980.0K) | ($6.49M) | - |
| Interest Expense | $42.0K | - | $21.0K | $32.0K | $42.0K | - | $21.0K | $21.0K | $23.0K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($1.68M) | - | ($1.78M) | ($2.60M) | ($10.24M) | - | ($5.38M) | $386.0K | ($6.45M) | - |
| EPS - Basic | ($0.13) | - | ($0.13) | ($0.20) | ($0.89) | - | ($0.46) | $0.04 | ($0.77) | - |
| EPS - Diluted | ($0.13) | - | ($0.13) | ($0.20) | ($0.89) | - | ($0.46) | $0.04 | ($0.77) | - |
Balance Sheet
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $308.0K | $638.0K | $1.95M | $975.0K | $1.85M | $5.86M | $2.88M | $7.89M | $4.32M | $13.27M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $4.89M | $3.90M | $4.84M | $7.48M | $6.13M | $3.69M | $4.33M | $6.11M | $9.84M | $6.63M |
| Current Assets | $842.0K | $1.02M | $2.22M | $1.33M | $2.16M | $5.98M | $7.84M | $13.02M | $9.57M | $13.60M |
| Total Assets | $842.0K | $1.02M | $2.22M | $1.40M | $2.43M | $10.28M | $10.71M | $17.50M | $13.05M | $17.43M |
| Current Liabilities | $14.04M | $12.89M | $11.77M | $9.38M | $8.53M | $7.07M | $7.62M | $9.37M | $11.96M | $11.49M |
| Long-term Debt | - | - | - | - | $150.0K | $159.0K | $164.0K | $400.0K | $779.0K | $779.0K |
| Total Liabilities | $14.04M | $12.89M | $11.77M | $9.38M | $8.68M | $7.22M | $7.82M | $9.89M | $13.11M | $12.87M |
| Stockholders' Equity | ($13.46M) | ($12.03M) | ($9.71M) | ($8.14M) | ($6.40M) | $2.89M | $2.71M | $7.50M | ($173.0K) | $4.42M |
| Retained Earnings | ($184.60M) | ($182.92M) | ($180.41M) | ($178.63M) | ($176.03M) | ($165.79M) | ($163.13M) | ($157.75M) | ($158.14M) | ($151.69M) |
Cash Flow
| Line item | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.44M) | - | - | - | ($4.01M) | - | - | - | ($4.94M) | - |
| Investing Cash Flow | - | - | - | - | $0 | - | - | - | $285.0K | - |
| Financing Cash Flow | $1.11M | - | - | - | $1.0K | - | - | - | $750.0K | - |
| CapEx | - | - | - | - | - | - | - | - | $0 | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($4.94M) | - |
Ratios
| Metric | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | -1993.0% | -19.0% | -2308.2% | - |
| EBITDA margin | - | - | - | - | - | - | -1985.5% | -18.6% | -2307.5% | - |
| Net margin | - | - | - | - | - | - | -2690.0% | 7.5% | -2295.7% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -1758.0% | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 0.77 | - |
| R&D / Revenue | - | - | - | - | - | - | 954.5% | 52.5% | 1011.7% | - |
| SG&A / Revenue | - | - | - | - | - | - | 1038.5% | 66.5% | 1396.4% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -199.0% | - | -80.3% | -186.1% | -420.8% | - | -50.3% | 2.2% | -49.4% | - |
| Return on equity | 12.5% | - | 18.4% | 32.0% | 159.9% | - | -198.2% | 5.1% | 3728.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.06 | 0.08 | 0.19 | 0.14 | 0.25 | 0.85 | 1.03 | 1.39 | 0.80 | 1.18 |
| Quick ratio | 0.06 | 0.08 | 0.19 | 0.14 | 0.25 | 0.85 | 1.03 | 1.39 | 0.80 | 1.18 |
| Cash ratio | 0.02 | 0.05 | 0.17 | 0.10 | 0.22 | 0.83 | 0.38 | 0.84 | 0.36 | 1.16 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | -0.02 | 0.06 | 0.06 | 0.05 | -4.50 | 0.18 |
| Debt / Assets | - | - | - | - | 0.06 | 0.02 | 0.02 | 0.02 | 0.06 | 0.04 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -48.1x | - | -97.9x | -80.9x | -152.5x | - | -189.8x | -46.7x | -282.0x | - |
| Equity multiplier | -0.06 | -0.08 | -0.23 | -0.17 | -0.38 | 3.56 | 3.94 | 2.33 | -75.43 | 3.94 |
| Liabilities / Assets | 16.67 | 12.65 | 5.31 | 6.70 | 3.57 | 0.70 | 0.73 | 0.57 | 1.00 | 0.74 |
| Efficiency | ||||||||||
| Asset turnover | - | - | 0.00 | 0.00 | 0.00 | - | 0.02 | 0.29 | 0.02 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | -100.0% | -100.0% | -100.0% | - | -85.7% | 211.5% | -72.5% | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | -21.5% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 68.5% | - | 48.4% | -164.1% | 1.2% | - | -13.8% | 80.6% | 48.5% | - |
| Net income growth (YoY) | 83.6% | - | 66.9% | - | -58.7% | - | -60.0% | - | 51.8% | - |
| EPS growth (YoY) | 85.4% | - | 71.7% | - | -15.6% | - | -48.4% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 37.3% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -110.2% | - | - | - | -3600.0% | -34.7% | -50.4% | -5.4% | - | -81.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$5.44M totalLicense$5.00M · 91.9%
Collaboration Revenue$442.0K · 8.1%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing KINETA against the 5 most active filers in the same SIC group.